

MOLECULAR PHARMACOLOGY PROGRAM

[Cancer Engineering](#)

The David Scheinberg Lab

[Research](#)

Research

[Alumni](#)



David A. Scheinberg, MD, PhD

Chair, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery

Professor

The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, engineered cells, and active specific agents such vaccines. An important goal is to take these new therapies

into human clinical trials for testing. Examples include a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in Phase II human trials (*Blood*, 2010), and a vaccine to WT1 in Phase III trials. Read full article in [Science](#) .

We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, humanized antibodies, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular proteins (*Science Trans. Med.*, 2013), (*Nature Biotech.*, 2015), as well as prototype targeted nano-machines (*Nature Nano*, 2013), and cellular micropharmacies (*Nature Chem.Biol.*, 2021).

Research Projects

- [Projects](#)



Featured News



[At Work: Center for Experimental Therapeutics Chair David Scheinberg](#)

A second-generation physician-scientist, David Scheinberg specializes in caring for patients with leukemia — and developing new ways to treat it.

ANNOUNCEMENT



[Innovative Partnership Will Speed Drug Discovery and Development](#)

Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients.

[Scientists ID Antibody That Might Boost Cancer Therapy](#)

Physician-scientist David Scheinberg discussed his discovery of a unique monoclonal antibody, a molecule that can be engineered to target specific prot...

[View All Featured News](#)

Publications Highlights

[Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O'Reilly RJ, Liu C, Scheinberg DA. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Science translational medicine. 2013;5\(176\):176ra33. Doi: 10.1126/scitranslmed.3005661. PubMed. PMCID: PMC3963696.](#)

Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, O'Reilly RJ, Scheinberg DA. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. *Nature biotechnology*. 2015;33(10):1079-86. Doi: 10.1038/nbt.3349. PubMed PMID: 26389576; PMCID: PMC4600043.

[View All Publications](#)

People



David A. Scheinberg, MD, PhD

Chair, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery

Professor

- Molecular Pharmacology Program Member David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.
- MD, PhD, Johns Hopkins University School of Medicine

 scheinbd@mskcc.org

Email Address


 [646-888-2190](tel:646-888-2190)

Office Phone

 [View physician profile](#)

Physician profile

Members




Lab

Alumni


Lab Affiliations

Lab News & Events


Michael Curcio
Research Assistant



Tao Dao
Senior Research Scientist




Tatyana Korontsvit
Research Assistant



Michael R. McDevitt
Laboratory Member



Zita Aretz
Graduate Student



Subha Baniya
Graduate Student




Raphael Geißen
Research Fellow

[Journal Club & Photo Album](#)

Jaeyop Lee
Instructor

Open Positions

To learn more about available postdoctoral opportunities, please visit our [Career Center](#)



Qianqian (Skylar) Lin
Graduate Student



Jeremy P. Meyerberg
Research Assistant



Kaitlyn Pierpont
Graduate Student



Stephanie Pierre
Graduate Student



Sarah Qureshy
Medical Student Research
Fellow Education



Ekaterina Revskaya
Senior Research Scientist
scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Get in Touch

✉ scheinbd@mskcc.org

Lab Head Email

📞 [646-888-2190](tel:646-888-2190)

Office Phone

📞 [646-888-2205](tel:646-888-2205)

Lab Phone

Lab Resources

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of



Akihiko Shiiya
Research Scholar



Sarah Sheridan
Graduate Student



Patrick Wallisch
Graduate Student

David A. Scheinberg discloses the following relationships and financial interests:

- **Actinium**
Equity; Intellectual Property Rights;
Professional Services and Activities
(Uncompensated)
- **Arvinas, Inc.**
Equity
- **Atengen, Inc.**
Equity; Professional Services and Activities
(Uncompensated)
- **Century Therapeutics**
Intellectual Property Rights
- **Epics Therapeutics S.A.**
Professional Services and Activities
- **Estrella Biopharma, Inc.**
Professional Services and Activities
- **Eureka Therapeutics Inc**
Equity; Professional Services and Activities

(Uncompensated)

- **Great Point Partners**
Equity; Professional Services and Activities
- **iovance Biotherapeutics, Inc.**
Equity
- **Lantheus Medical Imaging, Inc.**
Equity
- **Lilly Oncology**
Equity
- **Omnipotent Bio Holdings, Inc.**
Equity; Professional Services and Activities
- **Pfizer, Inc.**
Equity
- **Repertoire Immune Medicines, Inc.**
Professional Services and Activities
- **Sapience Therapeutics, Inc.**

Equity; Fiduciary Role / Position

- Sellas Life Science Group

Equity; Fiduciary Role / Position; Intellectual Property Rights

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#) . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at ecoi@mskcc.org .

[View all disclosures](https://www.sloankettering.edu/disclosures) (<https://www.sloankettering.edu/disclosures>)

© 2025 Louis V. Gerstner Jr. Graduate School of Biomedical Sciences Memorial Sloan Kettering Cancer Center